Back to News
Market Impact: 0.25
Celltrion Launches OMLYCLO, First Interchangeable Omalizumab Biosimilar In U.S.
Source: Nasdaq
Healthcare & BiotechProduct Launches
Celltrion USA said OMLYCLO (omalizumab-igec), described as the first and only FDA-approved interchangeable biosimilar to XOLAIR (omalizumab), is now commercially available in the U.S. The announcement marks the product’s U.S. commercial launch; no sales or market-impact figures were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- OKX debuts a platform that turns 50 currencies into digital dollars, betting emerging market investors want stablecoins
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Lucid Motors’ EV output falls to lowest level in almost two years
- Nvidia-backed Reflection AI unveils its first open model, Beam. Could it be America’s best chance to compete with China?
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?